Amgen's Research and Development leaders, a few of whom are pictured above, work to transform the science of today into the powerful medicines of tomorrow. From left to right: Ruth Lightfoot-Dunn, vice president, Preclinical Safety Assessment; Paul Pearson, vice president, Pharmacokinetics and Drug Metabolism; Chris Fibiger, vice president and global head, Neuroscience; Susan Hershenson, vice president, Pharmaceutics; and Glenn Begley, vice president, Hematology and Oncology Research.

The history of scientific progress is often told as a series of breakthrough moments. But as any scientist can tell you, those rare moments of success are woven together with countless moments of disappointment—of leads that led nowhere, of great ideas that never became more than ideas.

Disappointment and success, effort and end result—a complex braid of moments makes up the beautiful pattern of scientific inquiry. Every moment has a lesson to teach. Ultimately, it's the moments of real insight that come from perseverance, determination, and execution that move medicine forward. Those are the moments that matter the most—to patients, to healthcare providers, and to Amgen.

In our first 25 years, Amgen has been fortunate to play a part in many such moments. While we can't predict what extraordinary advances in medical care will be made possible by new technologies and discoveries in the next 25 years, we intend to contribute to as many of them as we can.

We expect many more changes as we head into the future—but some things will not change. Amgen will continue to combine visionary science and innovation with rational decision-making and rigorous execution—because our pipeline is our future. And we will never lose sight of our mission to serve patients—because that's what makes it all worthwhile.